Indivior Pharmaceuticals, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Indivior reported Q2 2026 total net revenue of $343M (+14% YoY) with record SUBLOCADE revenue of $253M (+21% YoY) and record adjusted EBITDA of $186M (+111% YoY). The company raised full-year 2026 guidance: total revenue to $1,295M–$1,365M (vs. prior $1,215M–$1,285M), SUBLOCADE revenue to $1,010M–$1,050M (vs. prior $950M–$990M), and adjusted EBITDA to $700M–$740M (vs. prior $620M–$660M). Simultaneously, Indivior announced a definitive merger agreement with Supernus Pharmaceuticals (all-stock, merger of equals) expected to close Q4 2026. In Q2, Indivior repurchased 4.7M shares for $175M; year-to-date repurchases totaled 8.6M shares for $300M at average price of $34.73.
Why this rating
Strong organic growth and margin expansion (54% adjusted EBITDA margin) are positive; merger adds scale and diversification. At $1.8B market cap, $80M+ guidance raise (~5% revenue uplift) and 68% EBITDA growth are material. Merger execution risk detracts from pure positive.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.